Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate. Article

Full Text via DOI: 10.1200/JCO.2021.39.15_suppl.4109 Web of Science: 000708120602209

Cited authors

  • Das S, Chauhan A, Du LP, Thomas K, Jacob A, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin DB, Ciombor KK, Goff LW, Bradshaw M, Delbeke D, Sandler MP, Berlin J, Ramirez RA

Publication date

  • 2021

Published in

International Standard Serial Number (ISSN)

  • 0732-183X

Number of pages

  • 2

Volume

  • 39

Issue

  • 15